Saltar al contenido
Merck

Testosterone regulates thyroid cancer progression by modifying tumor suppressor genes and tumor immunity.

Carcinogenesis (2015-01-13)
Lisa J Zhang, Yin Xiong, Naris Nilubol, Mei He, Swaroop Bommareddi, Xuguang Zhu, Li Jia, Zhen Xiao, Jeong-Won Park, Xia Xu, Dhaval Patel, Mark C Willingham, Sheue-Yann Cheng, Electron Kebebew
RESUMEN

Cancer gender disparity has been observed for a variety of human malignancies. Thyroid cancer is one such cancer with a higher incidence in women, but more aggressive disease in men. There is scant evidence on the role of sex hormones on cancer initiation/progression. Using a transgenic mouse model of follicular thyroid cancer (FTC), we found castration led to lower rates of cancer in females and less advanced cancer in males. Mechanistically, less advanced cancer in castrated males was due to increased expression of tumor suppressor (Glipr1, Sfrp1) and immune-regulatory genes and higher tumor infiltration with M1 macrophages and CD8 cells. Functional study showed that GLIPR1 reduced cell growth and increased chemokine secretion (Ccl5) that activates immune cells. Our data demonstrate that testosterone regulates thyroid cancer progression by reducing tumor suppressor gene expression and tumor immunity.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Fluorescein, for fluorescence, free acid
Sigma-Aldrich
Testosterone, ≥98%
Sigma-Aldrich
Testosterone, purum, ≥99.0% (HPLC)
Supelco
Testosterone solution, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®
Sigma-Aldrich
Fumitremorgin C, from Neosartorya fischeri, film
Sigma-Aldrich
MISSION® esiRNA, targeting mouse Glipr1
Sigma-Aldrich
MISSION® esiRNA, targeting human GLIPR1